Brings advanced focal ablation to prostate cancer patients in the Pacific Northwest LYON, France, September 28, 2021 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that University of Washington Medicine has acquired the company’s
Studies conducted at the University of Southern California and University of Miami represent the first U.S. publications detailing successful partial-gland ablation using high intensity focused ultrasound therapy to treat prostate cancer patients since FDA cleared the technology in 2015.
EDAP Announces Third Quarter Results Conference Call LYON, France, Nov. 14, 2007 (PRIME NEWSWIRE) -- EDAP TMS S.A. (Nasdaq:EDAP) the global leader in High Intensity Focused Ultrasound treatment of prostate cancer, announced it will release its third quarter 2007 financial results Monday, November
- Strong Q3 2023 U.S. Focal One ® HIFU procedure growth of +150% year-over-year - - Record nine months HIFU revenues reflecting growing demand - - Two additional Focal One systems already placed in the fourth quarter - - Announces immunotherapy clinical research collaboration with Mount Sinai,
LYON, France , March 10, 2016 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, today announced that Sylvester Comprehensive Cancer Center at the University of Miami is the first site in the U.S. to be fully certified in the use of Ablatherm Robotic HIFU.
Total company second quarter 2021 revenue of approximately EUR 10.4 million (USD $12.4 million) increased 11.8% year-over-year; first half 2021 total company revenue of EUR 20.7 million (USD $24.8 million) increased 22.5% During the second quarter, U.S.
- Record second quarter and first half revenue s of EUR 14.3 million (USD 15 .5 million) and EUR 29.1 million (USD 31.5 million), respectively - - Total HIFU Q 2 2023 year - over - year revenue growth of 63. 6 % - - S trong Q 2 2023 year-over-year U.S.
